Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.

Phase 2

Novartis Pharmaceuticals